JAN 2 2, 2003 35

I hereby certify that this correspondence is being deposited who have inted States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on January 13, 2003.

1/22/4014

INFORMATION DISCLOSURE STATEMENT Examining Group 1645 Patent Application Docket No. G-101US05REG Serial No. 10/051.681

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner

Unknown

RECEIVED

Art Unit

1645

JAN 2 4 2009

Applicant(s) :

Daniel Cohen and Ilya Chumakov

TECH CENTER 1600/2900

Serial No.

10/051,681

Filed

January 16, 2002

Conf. No.

1458

For

Treatment of CNS Disorders Using D-Amino Acid Oxidase and D-

Aspartate Oxidase Antagonists

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicants inadvertently omitted copies of references R85-97 from the IDS package submitted on December 16, 2002. Applicants apologize for any confusion this may cause and request consideration of these references at this time.

It is respectfully requested that the Examiner indicate consideration of the cited references by returning a copy of the attached form PTO/SB/08 with initials or other appropriate marks. If any additional fee is required, or to credit any overpayment, please use Deposit Account No. 19-0065.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.56, 1.97, and 1.98 are met by the foregoing statements.

Respectfully submitted.

Frank C. Eisenschenk

Patent Attorney

Registration No. 45,332

Phone No.:

352-375-8100 352-372-5800

Fax No.: Address:

Saliwanchik, Lloyd & Saliwanchik

A Professional Association 2421 N.W. 41st Street, Suite A-1 Gainesville, FL 32606-6669

FCE/jaj

Attachments: Form PTO/SB/08B (1 page)

Copies of references cited (13)

Under the Paper

control number

Sheet

PTO/SB/08B (10-01)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office U.S. DEPARTMENT OF COMMERCE

1995, no persons are required to respond to a collection of information unless it contains a valid OMB

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

of

C	omplete if Known	RECE	VED
Application Number	10/051,681	HECE	$V = \langle \cdot \rangle$
Filing Date	January 16, 2002		
First Named Inventor	D. Cohen et al.	JAN 2 4	280 -
Group Art Unit	1645		
Examiner Name	Unassigned 'T	ECH CENTER	a contound
Attorney Docket Number	r 101.US5.REG	COLL OF MICH	11000/2300

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²		
	R85	CRUZ, L.J. et al., "Mutual antagonism in the metabolism of D-valine and D-leucine and antagonism by their analogs", <i>Arch Biochem Biophys.</i> , 1969, 135(1):341-9, PubMed , PMID: 4391341.			
	R86	DE KOK, A. et al., "Studies on L-amino acid oxidase. I. Effects of pH and competitive inhibitors", Biochim Biophys Acta, 1968, 167(1): 35-47, PubMed, PMID: 5693709.			
	R87	DE MARCHI, W.J. et al., "The oxidation of glycine by D-amino acid oxidase in extracts of mammalian central nervous tissue", <i>J Neurochem.</i> , 1969, 16(3):355-61. PubMed, PMID: 4389537.			
	R88	MCFARLANE, I.G. et al., "Metabolism of leucine in protein-calorie-deficient rats", <i>Biochem J.</i> , 1969, 111(4):565-71, PubMed, PMID: 4388242.			
	R89	MECHER, T. et al., "Presence of L-amino-acid oxidase in the blood in pemphigus, dermatitis herpetiformis Duhring and herpes zoster", <i>Clin. Chim. Acta</i> , 1969, 24(1): 111-20, PubMed, PMID: 5780154.			
	R90	MIZON, J. et al., "Properties of turkey (Meleagris gallopavo L.) liver L-amino acid oxidase", Biochim Biophys Acta, 1970, 212(1):33-42 [article in French], PubMed, PMID 5500943.			
	R91	NEIMS, A.H. et al., "Distribution of D-amino acid oxidase in bovine and human nervous tissues", J Neurochem, 1966, 13(3):163-8, PubMed, PMID: 4380208.			
	R92	NISHIKIMI, M. et al., "The occurrence of superoxide anion in the reaction of reduced phenazine methosulfate and molecular oxygen", <i>Biochem Biophys Res Commun.</i> , 1972, 46(2):849-54, PubMed, PMID: 4400444.			
	R93	SHINWARI, M.A. et al., "Naturally occurring inhibition and activation of avian liver L-amino acid oxidase", 1967, 104(3): 53P – 54P, PubMed, PMID: 6049890.			
	R94	SINGER, S. et al., "The effects of the administration of sodium benzoate and diethylstilbestrol disulfate on the nepatic levels of several glucocorticoid-sensitive enzymes in adrenalectomized rats", Biochim Biophys Acta,. 1967, 146(2):443-51, PubMed, PMID: 4383683.			
	R95	SIVA SANKAR, D.V. et al., "The effect of chlorpromazine and of oxygen on the substrate-inhibition of L-amino acid oxidase", <i>Biochem. Med.</i> , 1975(1): 75-82, PubMed, PMID: 1212242.			
	R96	ZELLER, E.A. <i>et al.</i> , "Interaction of ophidian L-amino acid oxidase with its substrates and inhibitors: role of molecular geometry and electron distribution. Communication 6 on ophidian L-amino acid oxidases", <i>Helv. Chim. Acta</i> , 1974;57(8): 2406-20, PubMed, PMID: 4443288.			
	R97	ZIMMERMAN, S.E. <i>et al.</i> , "Immunochemical studies of L-amino acid oxidase", <i>Biochim Biophys Acta</i> , 1971, 229(1):260-70, PubMed, PMID: 5543611.			

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.